Skip to main content
Prelude Therapeutics Inc logo

Prelude Therapeutics Inc — Investor Relations & Filings

Ticker · PRLD ISIN · US74065P1012 US Manufacturing
Open in API
Filings indexed 356 across all filing types
Latest filing 2024-03-05 Director's Dealing
Country US United States of America
Listing US PRLD

About Prelude Therapeutics Inc

https://preludetx.com/

Prelude Therapeutics is a clinical-stage precision oncology company focused on discovering and developing innovative medicines for cancer patients with high unmet needs. The company's pipeline features small molecule therapies and leverages expertise in targeted protein degradation. Key development programs include highly selective KAT6A degraders for solid tumors, such as ER+ breast cancer, and mutant-selective JAK2V617F JH2 inhibitors for myeloproliferative neoplasms. Prelude is also advancing next-generation degrader antibody conjugates (DACs) with novel payloads. The company's science-driven approach targets critical cancer cell pathways to create potentially transformative treatments.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2024-03-05 English
PRIMARY DOCUMENT
Director's Dealing
2024-03-05 English
PRIMARY DOCUMENT
Director's Dealing
2024-03-05 English
PRIMARY DOCUMENT
Director's Dealing
2024-03-04 English
Regulatory Filings 2024
Regulatory Filings Classification · 60% confidence The provided document text appears to be encoded or encrypted and does not contain any readable content, keywords, regulatory headers, or references to specific report types, fiscal periods, or regulatory bodies. Without any discernible information or context, it is impossible to classify the document as any specific filing type. According to the fallback rule, when a document does not fit any specific category, it should be classified as a Regulatory Filing (RNS). The document length is 15,000 characters, which is substantial, but the content is not interpretable. Therefore, the best classification is RNS with moderate confidence due to lack of readable content.
2024-02-21 English
S-3
Capital/Financing Update Classification · 95% confidence The document is a Form S-3 Registration Statement filed with the SEC, which is used for registering securities for sale to the public. It includes a prospectus for the resale of shares by selling stockholders. The text contains detailed information about the offering, selling stockholders, plan of distribution, and legal matters. It is not an annual report, earnings release, or any other financial report but a capital markets filing related to securities registration and offering. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it is the actual registration statement, not just an announcement of a report, so it is not RPA or RNS. Hence, the classification is CAP with high confidence.
2024-02-16 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.